Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic) & Region - Global Forecasts to 2027
Updated on : March 06, 2023
The global metagenomic sequencing market in terms of revenue was estimated to be worth $1.9 billion in 2022 and is poised to reach $4.3 billion by 2027, growing at a CAGR of 18.4% from 2022 to 2027. Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields.
To know about the assumptions considered for the study, Request for Free Sample Report
Metagenomic Sequencing Market Dynamics
Drivers: Continuous technological innovations in NGS platforms
Continuous technological innovations in sequencers have enabled the introduction of efficient, portable, and easy-to-use NGS platforms, capable of providing rapid and accurate results and boasting improved turnaround times. The introduction of such products and technologies provides an immediate competitive edge to players; as a result, prominent companies are increasingly focusing on R&D to strengthen their market positions and shares.
For instance, in April 2019, Pacific Biosciences of California, Inc. (US) launched the Sequel II System. The new product reduces project costs and timelines by approximately eight times the data output compared to the previous Sequel System. In January 2019, Oxford Nanopore Technologies plc. (UK) launched PromethION 24 and PromethION 48. These systems offer high throughput, long read, and real-time direct nanopore sequencing data in a modular format. The iSeq 100 (Illumina) and Ion GeneStudio S5 System (Thermo Fisher Scientific) are other revolutionary platforms that ensure high sequencing efficiency at decreased costs.
Restraints: End-user budget constraints in developing countries
In developing countries, academic R&D is mostly dependent on external funding. Despite continuous efforts by governments and private bodies to provide funds for research across the globe, various research and academic institutes face budget constraints regarding the purchase and use of advanced and premium-priced equipment and technologies. Although the price of NGS sequencing has declined, NGS sequencers continue to be costly. Illumina’s most advanced sequencing platforms—NovaSeq 5000 and 6000—are priced at USD 850,000 and USD 985,000, respectively. These sequencers offer ~70% faster sequencing capabilities than most of Illumina’s existing platforms, which can further improve through system and software upgrades.
Pacific Biosciences of California, another leading player in the NGS market, provides its PacBio RS II at ~USD 750,000 and its latest sequencing platform—Sequel system—at ~USD 350,000. Though low-cost sequencing platforms such as the iSeq have been launched in the market, their cost is still considered high for several end users in developing APAC and LATAM countries. As a result, the use of advanced technologies such as NGS is limited in academic and research institutes in developing countries, which is hampering the adoption of related NGS products for metagenomics.
Opportunities: NGS data analysis using big data
The volume of data produced during whole-genome sequencing is usually in the range of terabytes. Managing such huge data is a major concern for the end users of NGS-based metagenomic sequencing. Data storage requirements can be quite complex due to inconsistencies in data formats and the lack of industry-wide standardization for data output from different NGS platforms. However, the application of big data technologies and AI for NGS analysis and the management of workflows has significantly increased the yield of NGS runs.
The amount of data produced during a sequencing run also increases with technological advancements in sequencing. According to a National Human Genome Research Institute report, as of July 2017, the sequencing of one human genome produces around 743 terabytes (743,000 gigabytes) of data compared to 16.2 gigabytes at the initial stage of the Human Genome Project in 2001. This huge amount of genomic data generated is beyond the capacity of human analysis and thus provides an opportunity for the application of advanced computing technologies for its assessment and analysis. In line with this, various companies are incorporating advanced computational technologies into their sequencing offerings. For instance,
- In January 2021, Illumina (US) launched Illumina Connected Analytics (ICA), a new and integrated bioinformatics solution to manage, analyze, and explore large volumes of multi-omics data.
- In 2020, Illumina (US) launched the TruSight Software Suite, which enables sample-to-report analysis for genetic disease testing, provides an integrated solution, and delivers valuable insights through easier genomic sequencing.
The development of advanced NGS solutions based on big data analytics and cloud computing for managing, storing, and retrieving the high volumes of data generated provides a great opportunity in the metagenomic sequencing market.
Challenges: Challenges associated with metagenomic NGS
Despite the potential of mNGS, there are many obstacles to clear before this technology can become part of the mainstream laboratory. Major challenges include interpreting findings such as distinguishing contamination and colonization from true pathogens, selecting and validating databases used for analyses, and predicting antimicrobial susceptibilities. While mNGS is analytically more sensitive than standard culturing methods, the necessary removal of vast amounts of human nucleic acid during sequencing preparation and the post-analytic process in some cases can decrease the sensitivity in comparison to targeted PCR approaches for many organisms.
Contamination of samples during specimen collection is a large concern given the increased analytical sensitivity of mNGS compared to standard culture methods. There needs to be a validated quality-control process for steps from assessing reagent purity to measuring adequate genome coverage controls. Bioinformatic quality controls are needed to ensure that high-quality and validated genomes are available with minimal database errors. Ideally, bioinformatic personnel would be available to interpret sequencing results for each test, which is not available at most clinical microbiological laboratories. The Federal Drug Administration (FDA) has collaborated with other federal agencies to curate a database entitled FDA-ARGOS (FDA-database for regulatory-grade microbial sequences), which has been useful to ensure that current mNGS results are reliable and accurate, but these resources need to be updated and maintained.
Another significant limitation of mNGS is that most nucleic acids in clinical samples are from the host, so the host genome dominates sequence reads. This can result in decreased analytical sensitivity for detecting pathogens present at a relatively low burden. As sequencing and bioinformatic processing power evolve, mNGS testing may likely play a major role in the microbiological diagnostic workflow in the future. However, this technology is highly complex, with uncertain clinical utility in current medical practice environments.
By product & service segment, the reagents & consumables segment accounted for the largest share of the metagenomic sequencing market in 2021.
Based on products & services, the market is segmented into reagents & consumables, instruments, services, and analysis & data interpretation solutions. The reagents & consumables segment accounted for the largest share of the market in 2021. Factors such as the development and commercialization of high-quality reagents and kits and the continuous requirement of sequencing reagents by end users are expected to drive the growth of this segment in the market.
By technology, the 16S rRNA sequencing segment accounted for the largest share of the metagenomic sequencing market in 2021.
Based on technology, the market is segmented into 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing & de novo assembly, and metatranscriptomics. The 16S rRNA sequencing segment accounted for the largest share of the market in 2021. The high accuracy and affordability offered by 16S rRNA sequencing, advancements in bioinformatics solutions, and the growing number of metagenomic research activities to identify and classify various bacterial strains are the major factors driving the growth of the 16S rRNA sequencing market.
By application, the drug discovery segment accounted for the largest share of the metagenomic sequencing market in 2021.
Based on applications, the market is segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological & environmental applications, veterinary applications, and other applications. The drug discovery segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing research activities for novel drug discovery and growing collaborations between market players, academic institutions, and pharmaceutical companies for drug development.
North America accounted for the largest share of the metagenomic sequencing market in 2021.
North America accounted for the largest share of the market in 2021. Factors such as the increasing applications of metagenomics in diagnostics and genomics research,the availability of research funding, and the development of NGS data analysis solutions are driving the growth of the market in North America.
To know about the assumptions considered for the study, download the pdf brochure
The metagenomic sequencing market is dominated by a few globally established players such as Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK).
Metagenomic Sequencing Market Report Scope:
|
Report Metric |
Details |
|
Market Size Available for Years |
2020–2027 |
|
Base Year Considered |
2021 |
|
Forecast Period |
2022–2027 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product & Service, Worklow, Technology, Application, and Region |
|
Geographies Covered |
North America, Europe, APAC, LATAM, and MEA |
|
Companies Covered |
The major market players include Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK) |
The study categorizes the metagenomic sequencing market into the following segments and sub-segments:
By Product & Service
- Reagents & Consumables
- Instruments
- Services
- Analysis & Data Interpretation Solutions
By Workflow
- Sample Processing & Library Preparation
- Sequencing
- Data Processing & Analysis
By Technology
- Shotgun Metagenomic Sequencing
- 16S rRNA Sequencing
- Metatranscriptomics
- Whole-genome Sequencing & De Novo Assembly
By Application
- Drug Discovery
- Clinical Diagnostics
- Soil Microbiome Applications
- Industrial applications
- Ecological and Environmental Applications
- Veterinary Applications
- Other Applications
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Rest of Europe
-
Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- The Middle East and Africa
Recent Developments
- In April 2019, Pacific Biosciences of California, Inc. (US) launched the Sequel II System. This system includes the new SMRT Cell 8M, chemistry, instrument control software, and the SMRT Link software package.
- In January 2021, Illumina, Inc. (US) collaborated with Helix to increase national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC.
- In June 2020, Illumina (US) acquired BlueBee, a cloud-based software company that provides genomic analysis solutions for research and clinical customers. Through this acquisition, Illumina enhanced its capabilities to analyze and interpret the data produced by its sequencing systems.
- In July 2021, QIAGEN N.V. (Netherlands) formed a strategic alliance with Sysmex Corporation for global cancer companion diagnostics development and commercialization using NGS and Plasma-Safe-SeqS technologies.
Frequently Asked Questions (FAQ):
What is the projected market value of the global metagenomic sequencing market?
The global market of metagenomic sequencing is projected to reach USD 4.3 billion.
What is the estimated growth rate (CAGR) of the global metagenomic sequencing market for the next five years?
The global metagenomic sequencing market is projected to grow at a Compound Annual Growth Rate (CAGR) of 18.4% from 2022 to 2027.
What are the major revenue pockets in the metagenomic sequencing market currently?
North America accounted for the largest share of the market in 2021. Factors such as the increasing applications of metagenomics in diagnostics and genomics research,the availability of research funding, and the development of NGS data analysis solutions are driving the growth of the market in North America.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 METAGENOMIC SEQUENCING MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
FIGURE 4 METAGENOMIC SEQUENCING MARKET: BREAKDOWN OF PRIMARIES
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE) – COLLECTIVE REVENUE OF ALL METAGENOMIC SEQUENCING PRODUCTS & SERVICES
FIGURE 7 MARKET: CAGR PROJECTIONS, 2022–2027
FIGURE 8 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
2.5 GROWTH RATE ASSUMPTIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 46)
FIGURE 10 METAGENOMIC SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MARKET, BY WORKFLOW, 2021
FIGURE 12 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MARKET SHARE, BY TECHNOLOGY, 2021
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE MARKET
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 METAGENOMIC SEQUENCING MARKET OVERVIEW
FIGURE 15 TECHNOLOGICAL INNOVATIONS IN NGS PLATFORMS—A KEY FACTOR DRIVING GROWTH IN THE MARKET
4.2 ASIA PACIFIC: MARKET, BY TECHNOLOGY & COUNTRY (2021)
FIGURE 16 16S RRNA SEQUENCING TECHNOLOGY ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
4.3 MARKET SHARE FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2021
FIGURE 17 ENERGY APPLICATION SEGMENT DOMINATED THE MARKET IN 2021
5 MARKET OVERVIEW (Page No. - 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 METAGENOMIC SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Continuous technological innovations in NGS platforms
5.2.1.1.1 iSeq 100 System
5.2.1.1.2 Ion GeneStudio S5
5.2.1.2 Initiatives and funding from government & private bodies for large-scale sequencing projects
TABLE 1 GLOBAL SEQUENCING INITIATIVES
5.2.1.3 Declining costs of genome sequencing
FIGURE 19 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2020
5.2.1.4 Significant applications of metagenomics in various fields
5.2.2 RESTRAINTS
5.2.2.1 End-user budget constraints in developing countries
5.2.3 OPPORTUNITIES
5.2.3.1 NGS data analysis using big data
FIGURE 20 DATA PRODUCTION DURING HUMAN WHOLE-GENOME SEQUENCING, 2001–2019
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with metagenomic NGS
5.3 IMPACT OF COVID-19 ON THE MARKET
5.4 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 METAGENOMIC SEQUENCING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.4.1 THREAT OF NEW ENTRANTS
5.4.2 THREAT OF SUBSTITUTES
5.4.3 BARGAINING POWER OF SUPPLIERS
5.4.4 BARGAINING POWER OF BUYERS
5.4.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.5 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS OF THE MARKET: MANUFACTURING AND ASSEMBLY PHASES ADD MAXIMUM VALUE
FIGURE 22 VALUE CHAIN: METAGENOMIC SEQUENCING ANALYSIS WORKFLOW —MAXIMUM VALUE IS ADDED DURING THE SEQUENCING AND ANALYSIS PHASES
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 ECOSYSTEM ANALYSIS: MARKET
TABLE 3 SUPPLY CHAIN ECOSYSTEM
5.7 PATENT ANALYSIS
5.7.1 TOP 10 GRANTED PATENT OWNERS IN THE LAST 20 YEARS
5.7.2 TOP 10 PLAYERS WITH THE HIGHEST NO. OF PATENT APPLICATIONS
5.7.3 LIST OF RECENT PATENTS
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 24 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.1.1 US
TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.9.1.2 Canada
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
TABLE 6 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.9.3.2 Japan
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.5 MIDDLE EAST
5.10 PRICING ANALYSIS
TABLE 7 AVERAGE SELLING PRICE OF NGS SYSTEMS (2020)
5.11 RANGES/SCENARIOS
FIGURE 25 DEPENDING ON HOW THE UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE MARKET
5.12 TRADE ANALYSIS
5.12.1 TRADE ANALYSIS FOR MARKET
TABLE 8 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2016-2020 (USD THOUSAND)
TABLE 9 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2016-2020 (USD THOUSAND)
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.14 KEY CONFERENCES & EVENTS, 2022
TABLE 10 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
TABLE 11 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP THREE APPLICATIONS (%)
TABLE 12 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
6 METAGENOMIC SEQUENCING MARKET, BY PRODUCT & SERVICE (Page No. - 79)
6.1 INTRODUCTION
TABLE 13 MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 REAGENTS & CONSUMABLES
6.2.1 RISING ADOPTION OF METAGENOMIC SEQUENCING IS DRIVING THE USE OF REAGENTS & CONSUMABLES
TABLE 14 METAGENOMIC SEQUENCING REAGENTS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 NORTH AMERICA: METAGENOMIC SEQUENCING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 EUROPE: METAGENOMIC SEQUENCING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 APAC: METAGENOMIC SEQUENCING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LAUNCH OF ADVANCED NGS PLATFORMS WILL SUPPORT THE GROWTH OF THIS SEGMENT
TABLE 18 METAGENOMIC SEQUENCING INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: METAGENOMIC SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: METAGENOMIC SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 APAC: METAGENOMIC SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SERVICES
6.4.1 TIME AND COST-EFFECTIVENESS OF OUTSOURCING NGS PROJECTS HAS DRIVEN THE DEMAND FOR SERVICES
TABLE 22 METAGENOMIC SEQUENCING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 23 NORTH AMERICA: METAGENOMIC SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 EUROPE: METAGENOMIC SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 APAC: METAGENOMIC SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 ANALYSIS & DATA INTERPRETATION SOLUTIONS
6.5.1 LIMITED TECHNICAL KNOWLEDGE OF ADVANCED ANALYSIS SOLUTIONS AMONG END USERS TO HAMPER MARKET GROWTH
TABLE 26 METAGENOMIC SEQUENCING ANALYSIS & DATA INTERPRETATION SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NORTH AMERICA: METAGENOMIC SEQUENCING ANALYSIS & DATA INTERPRETATION SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: METAGENOMIC SEQUENCING ANALYSIS & DATA INTERPRETATION SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 APAC: METAGENOMIC SEQUENCING ANALYSIS & DATA INTERPRETATION SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (Page No. - 88)
7.1 INTRODUCTION
TABLE 30 MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
7.2 SAMPLE PROCESSING & LIBRARY PREPARATION
7.2.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED SAMPLE PROCESSING AND LIBRARY PREPARATION ASSAY KITS IS DRIVING MARKET GROWTH
TABLE 31 SAMPLE PROCESSING & LIBRARY PREPARATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: SAMPLE PROCESSING & LIBRARY PREPARATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 EUROPE: SAMPLE PROCESSING & LIBRARY PREPARATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 APAC: SAMPLE PROCESSING & LIBRARY PREPARATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 SEQUENCING
7.3.1 SANGER SEQUENCING HAS BEEN SUPPLANTED BY NGS DUE TO ITS ADVANTAGES AND RAPIDITY
TABLE 35 SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 APAC: SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 DATA PROCESSING & ANALYSIS
7.4.1 NEED FOR SKILLED PERSONNEL TO OPERATE DATA PROCESSING AND ANALYTICS TOOLS HAS SLOWED MARKET GROWTH
TABLE 39 DATA PROCESSING & ANALYSIS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: DATA PROCESSING & ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: DATA PROCESSING & ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 APAC: DATA PROCESSING & ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (Page No. - 96)
8.1 INTRODUCTION
TABLE 43 MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 16S RRNA SEQUENCING
8.2.1 16S RRNA SEQUENCING IS A COST-EFFECTIVE TECHNIQUE FOR THE IDENTIFICATION OF BACTERIAL STRAINS
TABLE 44 16S RRNA SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: 16S RRNA SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 EUROPE: 16S RRNA SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 APAC: 16S RRNA SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 SHOTGUN METAGENOMIC SEQUENCING
8.3.1 SHOTGUN METAGENOMIC SEQUENCING SEGMENT TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
TABLE 48 SHOTGUN METAGENOMIC-SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: SHOTGUN METAGENOMIC-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: SHOTGUN METAGENOMIC-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 APAC: SHOTGUN METAGENOMIC-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY
8.4.1 WGS HELPS GENERATE ACCURATE REFERENCE GENOMES FOR MICROBIAL IDENTIFICATION
TABLE 52 WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 APAC: WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 METATRANSCRIPTOMICS
8.5.1 METATRANSCRIPTOMICS HELPS IN THE UNDERSTANDING OF THE ACTIVE FUNCTIONAL PROFILE OF A MICROBIAL COMMUNITY
TABLE 56 METATRANSCRIPTOMICS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: METATRANSCRIPTOMICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: METATRANSCRIPTOMICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 APAC: METATRANSCRIPTOMICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 METAGENOMIC SEQUENCING MARKET, BY APPLICATION (Page No. - 106)
9.1 INTRODUCTION
TABLE 60 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 DRUG DISCOVERY
9.2.1 DRUG DISCOVERY ACCOUNTS FOR THE LARGEST SHARE OF THE MARKET
TABLE 61 MARKET FOR DRUG DISCOVERY, BY REGION, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 APAC: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
9.3.1 ADVANTAGES OF METAGENOMIC NGS HAVE ENABLED WIDE APPLICATIONS IN DIAGNOSTICS
TABLE 65 MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 EUROPE: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 APAC: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 SOIL MICROBIOME APPLICATIONS
9.4.1 NORTH AMERICA SHOWS HIGH DEMAND FOR METAGENOMIC SEQUENCING IN SOIL MICROBIOME APPLICATIONS
TABLE 69 MARKET FOR SOIL MICROBIOME APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET FOR SOIL MICROBIOME APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: MARKET FOR SOIL MICROBIOME APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 APAC: MARKET FOR SOIL MICROBIOME APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 INDUSTRIAL APPLICATIONS
TABLE 73 MARKET FOR INDUSTRIAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 APAC: MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.5.1 ENERGY
9.5.1.1 Declining fossil fuel reserves and growing energy needs will drive market growth
TABLE 78 MARKET FOR ENERGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 79 NORTH AMERICA: MARKET FOR ENERGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: MARKET FOR ENERGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 81 APAC: MARKET FOR ENERGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.5.2 BIOREMEDIATION
9.5.2.1 Need to monitor pollutant impact and contamination will provide opportunities for metagenomic sequencing in bioremediation
TABLE 82 MARKET FOR BIOREMEDIATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR BIOREMEDIATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: MARKET FOR BIOREMEDIATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 APAC: MARKET FOR BIOREMEDIATION, BY COUNTRY, 2020–2027 (USD MILLION)
9.5.3 OTHER INDUSTRIAL APPLICATIONS
TABLE 86 MARKET FOR OTHER INDUSTRIAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET FOR OTHER INDUSTRIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: MARKET FOR OTHER INDUSTRIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 89 APAC: MARKET FOR OTHER INDUSTRIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.6 ECOLOGICAL & ENVIRONMENTAL APPLICATIONS
9.6.1 METAGENOMIC SEQUENCING CAN HELP IDENTIFY INVASIVE AND ENDANGERED SPECIES
TABLE 90 MARKET FOR ECOLOGICAL & ENVIRONMENTAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 91 NORTH AMERICA: MARKET FOR ECOLOGICAL & ENVIRONMENTAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 EUROPE: MARKET FOR ECOLOGICAL & ENVIRONMENTAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 93 APAC: MARKET FOR ECOLOGICAL & ENVIRONMENTAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.7 VETERINARY APPLICATIONS
9.7.1 DEMAND FOR RAPID AND ACCURATE PATHOGEN DIAGNOSIS IS SUPPORTING THE DEMAND FOR SEQUENCING
TABLE 94 MARKET FOR VETERINARY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET FOR VETERINARY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 96 EUROPE: MARKET FOR VETERINARY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 97 APAC: MARKET FOR VETERINARY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.8 OTHER APPLICATIONS
TABLE 98 MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 100 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 101 APAC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10 METAGENOMIC SEQUENCING MARKET, BY REGION (Page No. - 125)
10.1 INTRODUCTION
TABLE 102 MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: MARKET SNAPSHOT
TABLE 103 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 NORTH AMERICA: MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 105 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 106 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 108 NORTH AMERICA: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Well-established infrastructure and funding sources available for NGS-based small- and medium-sized research projects make the US the largest market in North America
TABLE 109 US: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 110 US: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 111 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 112 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 113 US: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives and workshops to support growth in this market
TABLE 114 CANADA: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 115 CANADA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 116 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 117 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 118 CANADA: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 119 EUROPE: METAGENOMIC SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 122 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 123 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany has witnessed a significant increase in investments in next-generation technologies, making it the largest market in Europe
TABLE 125 GERMANY: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 126 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 127 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 128 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 129 GERMANY: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Government initiatives to support genomics research drive growth in the market in France
TABLE 130 FRANCE: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 131 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 132 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 133 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 134 FRANCE: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.3.3 UK
10.3.3.1 Favorable funding scenario for genomics research in the country to support the adoption of NGS
TABLE 135 UK: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 136 UK: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 137 UK: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 138 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 139 UK: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.3.4 REST OF EUROPE
TABLE 140 ROE: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 141 ROE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 142 ROE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 143 ROE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 144 ROE: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: METAGENOMIC SEQUENCING MARKET SNAPSHOT
TABLE 145 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 146 ASIA PACIFIC: MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 147 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Several key market players are focusing on strengthening their presence and offerings in China—a key factor driving market growth
TABLE 151 CHINA: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 152 CHINA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 153 CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 154 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 155 CHINA: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Rising use of metagenomic sequencing for various applications to drive market growth in Japan
TABLE 156 JAPAN: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 157 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 158 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 159 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 160 JAPAN: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing adoption of strategies such as collaborations and partnerships by various private and government bodies to drive market growth
TABLE 161 INDIA: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 162 INDIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 163 INDIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 164 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 165 INDIA: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 166 ROAPAC: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 167 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 168 ROAPAC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 169 ROAPAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 170 ROAPAC: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4.5 LATIN AMERICA
10.4.5.1 Introduction of low-cost sequencing technologies is expected to drive the market
TABLE 171 LATAM: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 172 LATAM: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 173 LATAM: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 174 LATAM: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 175 LATAM: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
10.4.6 MIDDLE EAST & AFRICA
10.4.6.1 Rising awareness of advanced sequencing technologies is expected to drive market growth in the coming years
TABLE 176 MEA: METAGENOMIC SEQUENCING MARKET, BY WORKFLOW, 2020–2027 (USD MILLION)
TABLE 177 MEA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 178 MEA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 179 MEA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 180 MEA: MARKET FOR INDUSTRIAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 170)
11.1 KEY PLAYER STRATEGIES
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE METAGENOMIC SEQUENCING MARKET
11.2 MARKET SHARE ANALYSIS
FIGURE 29 MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2020
TABLE 181 MARKET: DEGREE OF COMPETITION
11.3 REVENUE ANALYSIS
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2018-2021)
11.4 COMPANY EVALUATION QUADRANT
FIGURE 31 MARKET: COMPANY EVALUATION MATRIX, 2021
11.4.1 STARS
11.4.2 PERVASIVE PLAYERS
11.4.3 EMERGING LEADERS
11.4.4 PARTICIPANTS
11.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS)
FIGURE 32 MARKET: COMPANY EVALUATION MATRIX FOR START-UPS, 2021
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 DYNAMIC COMPANIES
11.5.4 RESPONSIVE COMPANIES
11.6 COMPETITIVE BENCHMARKING
TABLE 182 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 183 COMPANY REGION FOOTPRINT (25 COMPANIES)
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES
TABLE 184 MARKET: PRODUCT LAUNCHES, JANUARY 2018-FEBRUARY 2022
11.7.2 DEALS
TABLE 185 MARKET: DEALS, JANUARY 2018-FEBRUARY 2022
11.7.3 OTHER DEVELOPMENTS
TABLE 186 MARKET: OTHER DEVELOPMENTS, JANUARY 2018-FEBRUARY 2022
12 COMPANY PROFILES (Page No. - 182)
12.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ILLUMINA, INC.
TABLE 187 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
12.1.2 THERMO FISHER SCIENTIFIC, INC.
TABLE 188 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.3 QIAGEN N.V.
TABLE 189 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.4 PERKINELMER, INC.
TABLE 190 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 36 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
12.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC.
TABLE 191 OXFORD NANOPORE TECHNOLOGIES, PLC.: BUSINESS OVERVIEW
12.1.6 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
TABLE 192 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: BUSINESS OVERVIEW
FIGURE 37 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY SNAPSHOT (2020)
12.1.7 BGI GROUP
TABLE 193 BGI GROUP: BUSINESS OVERVIEW
12.1.8 PSOMAGEN, INC.
TABLE 194 PSOMAGEN, INC.: BUSINESS OVERVIEW
12.1.9 EUROFINS SCIENTIFIC
TABLE 195 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
12.1.10 BROOKS AUTOMATION, INC.
TABLE 196 BROOKS AUTOMATION, INC.: BUSINESS OVERVIEW
FIGURE 39 BROOKS AUTOMATION, INC.: COMPANY SNAPSHOT (2020)
12.1.11 NOVOGENE CO., LTD.
TABLE 197 NOVOGENE CO., LTD.: BUSINESS OVERVIEW
12.1.12 ZYMO RESEARCH CORPORATION
TABLE 198 ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW
12.1.13 TECAN TRADING AG
TABLE 199 TECAN TRADING AG: BUSINESS OVERVIEW
FIGURE 40 TECAN TRADING AG: COMPANY SNAPSHOT (2020)
12.1.14 INTEGRAGEN SA
TABLE 200 INTEGRAGEN SA: BUSINESS OVERVIEW
FIGURE 41 INTEGRAGEN SA: COMPANY SNAPSHOT (2020)
12.1.15 MICROSYNTH AG
TABLE 201 MICROSYNTH AG: BUSINESS OVERVIEW
12.1.16 DNASTAR, INC.
TABLE 202 DNASTAR: BUSINESS OVERVIEW
12.2 OTHER COMPANIES
12.2.1 COSMOSID, INC.
TABLE 203 COSMOSID, INC.: COMPANY OVERVIEW
12.2.2 GENEXA AG
TABLE 204 GENEXA AG.: COMPANY OVERVIEW
12.2.3 VARIGEN BIOSCIENCES CORPORATION
TABLE 205 VARIGEN BIOSCIENCES: COMPANY OVERVIEW
12.2.4 VERITAS GENETICS
TABLE 206 VERITAS GENETICS: COMPANY OVERVIEW
12.2.5 SINGENE
TABLE 207 SINGENE: COMPANY OVERVIEW
12.2.6 METAGENOMI
TABLE 208 METAGENOMI: COMPANY OVERVIEW
12.2.7 COMPUTOMICS
TABLE 209 COMPUTOMICS: COMPANY OVERVIEW
12.2.8 IDBYDNA, INC.
TABLE 210 IDBYDNA, INC.: COMPANY OVERVIEW
12.2.9 INTACT GENOMICS, INC.
TABLE 211 INTACT GENOMICS, INC. COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 240)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global metagenomic sequencing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the metagenomic sequencing market (estimated through various secondary research approaches) was then triangulated with primary research inputs to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from organizations such as the World Health Organization (WHO), Institute of Bioinformatics and Applied Biotechnology (IBAB), National Institutes of Health (NIH), Joint Genome Institute (JGI), National Human Genome Research Institute (NHGRI), National Center for Biotechnology Information (NCBI), Personalized Medicine Partnership for Cancer (PMPC), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute (EMBL), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Biotechnology and Biological Sciences Research Council (BBSRC), Department of Biotechnology (DBT), SciGenom Research Foundation (SGRF), and Malaysian Genomics Resource Centre.
Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global metagenomics sequencing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global metagenomic sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from academic & research centers, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs) and supply side (such as C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering metagenomic sequencing products & services) across five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the overall size of the metagenomic sequencing market through the methodology mentioned above, this market was split into several segments and subsegments. Market breakdown procedures were employed, wherever applicable, to arrive at the exact market value for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand and supply-side participants.
Report Objectives
- To define, describe, and forecast the global metagenomic sequencing market by product & service, workflow, technology, application, and region
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To strategically analyze the market structure and profile the key players of the global metagenomic sequencing market and comprehensively analyze their core competencies2
- To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the metagenomic sequencing market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization option is available for the report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top 3 companies
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Geographical Analysis
- Further breakdown of the RoE metagenomic sequencing market into countries
- Further breakdown of the RoAPAC metagenomic sequencing market into countries
- Further breakdown of the LATAM metagenomic sequencing market into countries
Growth opportunities and latent adjacency in Metagenomic Sequencing Market
Can you please share some insights on Metagenomics Sequencing Market Size | Industry Growth, 2028 ?
What is the market share of Metagenomic Sequencing Market Growth, Size in 2030 ?
Which are the major growth restraining factors for the global Metagenomic Sequencing Market?